Project Grant R01CA303584
Award Date
6/23/25
Completion Date
5/31/30
Dollars Obligated
$610K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
This $177,058 Project Grant awarded by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) supports research to discover and optimize novel anti-mitotic agents for the treatment of metastatic melanoma. The grant aims to develop fused heterocyclic pyrazine (FHP) based tubulin inhibitors that can overcome drug resistance and reduce toxicity associated with current treatments. The research involves three key...
The National Cancer Institute (NCI) awarded Celdara Medical, LLC a $1,024,967 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to develop CM-HZ01, a novel non-alpha-IL2 therapeutic for the treatment of metastatic melanoma. The goal is to advance CM-HZ01 to Investigational New Drug (IND) status, providing a potentially best-in-class immunotherapy option for patients with limited effective treatments for this deadly form of skin cancer. The project period runs from January...
This $463,375 federal Project Grant award from the National Institute of Environmental Health Sciences (NIEHS) under the Environmental Health program (CFDA 93.113) supports research at the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. in Tampa, Florida. The research aims to identify and characterize the role of melanin-carbonyl-DNA (MCD) and melanin-carbonyl-protein (MCP) adducts in the progression and treatment resistance of NRAS mutant melanoma. The key objectives are to...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $415,500.00 to Chapman University to develop and evaluate peptide-doxorubicin conjugates for mitigating cardiotoxicity and overcoming drug resistance in cancer. The key objectives are to investigate the mechanisms by which these peptide-drug conjugates can selectively target and kill drug-resistant cancer cells while reducing adverse cardiotoxic effects, and to conduct in vivo...
This Project Grant award from the National Cancer Institute (NCI), under the federal Cancer Biology Research program (CFDA 93.396), provides $442,236 to the University of Alabama at Birmingham (UAB) from January 1, 2025 through December 31, 2029. The funding supports research to uncover a novel melanoma metastasis pathway driven by the YTHDF1 RNA-binding protein, and to evaluate therapeutic targeting of the IMPDH1 and TRKB/BDNF pathways that mediate this process. The research utilizes...
This Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) provides $661,072 to Northwestern University to develop a novel, first-in-class small molecule inhibitor that targets the USP22 oncogene. The goal is to create a therapy with dual immuno-activating and cancer-targeting efficacy to treat triple negative breast cancer. The research, conducted in partnership with startup company Exomira Medicine Inc., aims to advance the therapeutic...
This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $198,103 to New York University School of Medicine to conduct research on melanoma bone metastasis. The goal is to better understand how melanoma cells infiltrate the bone microenvironment and interact with the immune system, in order to develop improved treatments for melanoma patients with bone metastases. The 2-year project will utilize preclinical murine models to examine the role...
This federal Project Grant award of $154,000.00 from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training program (CFDA 93.859) is supporting research at Nova Southeastern University to validate targeting spliceosomal proteins HNRNPH1 and H2 as a novel approach for melanoma-targeted and immunotherapy. The key objectives are to: (1) determine the efficacy of specific spliceosomal inhibitors in in vivo models of human melanoma, (2) investigate the...
This $312,892 Project Grant, awarded by the National Cancer Institute (NCI) under the Cancer Research Manpower (CFDA 93.398) program, supports research at Duke University to investigate the role of type 3 innate lymphoid cells (ILC3s) in regulating the melanoma tumor microenvironment. The goal is to better understand how ILC3s and their secretion of interleukin-17 (IL-17) can create an immunosuppressive environment that hinders the effectiveness of immune checkpoint inhibitor (ICI) therapy for...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $217,863 to the University of Colorado-Denver to compare natural killer (NK) cell profiles within melanoma tumors and during pregnancy. The objectives are to: 1) identify biomarkers that can predict risk of disease progression and response to immune checkpoint blockade (ICB) therapy for melanoma patients, and 2) define new therapeutic targets to limit disease progression or improve...